The mission of the Multiple Myeloma Research Foundation (MMRF) is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. We are committed to funding research, educating and supporting people with myeloma, family members, caregivers, and healthcare professionals about the disease and today's most promising treatment options.
In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.
In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.
"In the midst of all of the difficulty of trying to deal with something this terrible, having that hope in your back pocket is invaluable to my life and to my family." - Brian Smith, on living with multiple myeloma and participating in Moving Mountains for Multiple Myeloma's recent Iceland trek.
MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds
A team of six bicyclists trekked across country, from California to Connecticut, to fundraise for the Multiple Myeloma Research Foundation.
Multiple myeloma advocate Eric Gelber makes history. Watch him as he makes his 200-mile journey.
For years, Eric Gelber has been embarking on long distance runs to raise money for the Multiple Myeloma Research Foundation. This September, he will attempt his longest run yet: 200 miles through Central Park over the course of a weekend
The Multiple Myeloma Research Foundation provides educational programs to help people with myeloma, family members, caregivers, and healthcare professionals learn more about the disease and today's most promising treatment options, including clinical trials, from leading multiple myeloma doctors and researchers.
Anne Quinn Young, of the Multiple Myeloma Research Foundation, discusses some of the antibodies that are being studied in multiple myeloma.
Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.